Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | PPID | Q08752 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16839762 | 0.91 | ALDH1A1 (0.58) | SMN1; SMN2EPHX2PPARGALDH1A1MEN1 | |
| SCHEMBL21246222 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2PPIDMAPTALDH1A1MEN1 | |
| SCHEMBL16839868 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2PPIDMEN1KMT2AATM | |
| SCHEMBL1161723 | 0.87 | MAPT (0.55) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL12548382 | 0.87 | MAPT (0.55) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23102214 | 0.87 | MAPT (0.55) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL25346616 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2MMP8PPIDEPHX2PPARG | |
| SCHEMBL16839851 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL334806 | 0.85 | LMNA (0.51) | SMN1; SMN2EPHX2PPARGMAPTMEN1 | |
| SCHEMBL16839777 | 0.85 | MEN1 (0.52) | SMN1; SMN2EPHX2MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| WO-2019023468-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| EP-0562042-A1 | QUINOLINE, NAPHTHYRIDINE AND PYRIDOBENZOXAZINE DERIVATIVES | ABBOTT LABORATORIES (US) | 1993-09-29 | — | — | EP | disclosed |
| US-5137892-A | Bactericides | ABBOTT LABORATORIES (US) | 1992-08-11 | — | — | US | disclosed |
| WO-1992010191-A1 | QUINOLINE, NAPHTHYRIDINE AND PYRIDOBENZOXAZINE DERIVATIVES | ABBOTT LABORATORIES (US) | 1992-06-25 | — | — | WO | disclosed |
| US-4997943-A | Bactericides | SANKYO COMPANY LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0208210-B1 | PYRIDONECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4753953-A | Pyridonecarboxylic acid derivatives and antibacterial pharmaceutical compositions thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0241206-A2 | Quinoline-3-carboxylic acid derivatives, their preparation and use | Sankyo Company Limited (JP) | 1987-10-14 | — | — | EP | disclosed |
| EP-0208210-A1 | Pyridonecarboxylic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SMN1; SMN2 1145/4885MMP8 4687/4885PPID 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.